Financing ·
Tyra Biosciences, Inc. priced an underwritten public offering on September 14, 2026, raising approximately $400…
TYRATyra Biosciences, Inc.
Tyra Biosciences, Inc. priced an underwritten public offering on September 14, 2026, raising approximately $400 million in gross proceeds before expenses. The company sold 9,079,000 shares of common stock at $22.03 per share and issued pre-funded warrants for 9,078,529 additional shares at $22.029 each to certain investors. Jefferies LLC, Guggenheim Securities, Cantor Fitzgerald & Co., and Barclays Capital Inc. served as underwriters. The offering is expected to close on September 15, 2026. Tyra intends to use the net proceeds to advance its dabogratinib development strategy for low-grade upper tract urothelial carcinoma, non-muscle invasive bladder cancer, and achondroplasia, as well as for preclinical programs and general corporate purposes. Tyra Biosciences is a clinical-stage biotechnology company focused on developing precision medicines targeting FGFR biology.